Molecular Templates (NASDAQ: MTEM)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.380 | ||||||
REV | 8.486M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Molecular Templates (NASDAQ: MTEM) through any online brokerage.
Other companies in Molecular Templates’s space includes: Orchard Therapeutics (NASDAQ:ORTX), 89bio (NASDAQ:ETNB), Bolt Biotherapeutics (NASDAQ:BOLT), Infinity Pharmaceuticals (NASDAQ:INFI) and Gemini Therapeutics (NASDAQ:GMTX).
The latest price target for Molecular Templates (NASDAQ: MTEM) was reported by Barclays on Wednesday, March 30, 2022. The analyst firm set a price target for 4.50 expecting MTEM to rise to within 12 months (a possible 341.18% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Molecular Templates (NASDAQ: MTEM) is $1.02 last updated May 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Molecular Templates.
Molecular Templates’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Molecular Templates.
Molecular Templates is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.